[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,75,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100403801","phase-4-bone-and-joint-infections---simplifying-treatment-in-children-trial-100403801",false,"NCT04538053","BonE and Joint Infections - Simplifying Treatment in Children Trial","BEST","Inclusion Criteria:\n\n* Children aged 1 to 18 years with acute, uncomplicated, community-acquired bone and joint infection who fulfil pre-defined clinical criteria.\n\nExclusion Criteria:\n\n1. Infection due to bacteria resistant to cefalexin or atypical infection (e.g. mycobacterial, fungal)\n2. Features of sepsis as defined by the presence of organ dysfunction (defined using definitions within the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score)\n3. Concomitant severe, invasive infection e.g. necrosing fasciitis\n4. Complicated infection (e.g. presence of prosthetic material; large subperiosteal (\\>3mm) or soft tissue abscess without surgical intervention; infection secondary to or complicated by trauma)\n5. History of allergy to cephalosporin antibiotics or immediate, severe reaction to penicillins\n6. Received more than three IV or oral dose of an antibiotic with activity against the likely bacteria causing the current infection\n7. Prior episode of OM or SA\n8. Prior condition predisposing to poor absorption (e.g. inflammatory bowel disease, current gastrointestinal symptoms) or complicated disease (e.g. immunodeficiency)\n9. Prior enrolment in the trial\n10. Current recipient of another investigational product as part of a clinical trial","ALL","1 Year","18 Years",{"count":20,"type":21},285,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a multi- centre trial of children with bone and joint infections (BJIs) at eight major paediatric hospitals in Australia and New Zealand. The primary objective is to establish if in children with acute, uncomplicated BJIs, entirely oral antibiotic treatment is not inferior to initial intravenous (IV) treatment for 1 to 7 days followed by an oral antibiotic course in achieving full recovery 3 months after presentation. Children will be randomly allocated to the 'entirely oral antibiotic' group or the 'standard treatment' group.",[27,28,29,30],"Bone Infection","Septic Arthritis","Bone and Joint Infection","Osteomyelitis","RECRUITING","2025-11-14",{"date":34,"type":35},"2025-11-17","ACTUAL",{"date":37,"type":35},"2021-06-01",{"date":39,"type":21},"2026-12",{"name":41,"class":42},"Murdoch Childrens Research Institute","OTHER",10,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100579684","initial-oral-antibiotics-for-bone-and-joint-infections-in-children-100579684","NCT06827496","Initial Oral Antibiotics for Bone and Joint Infections in Children","Initial Oral Antibiotics for Bone and Joint Infections in Children: A Prospective Nationwide Real-world Effectiveness Study in Denmark","Children and adolescents aged 3 months to 17 years with uncomplicated bone and joint infections treated with initial oral antibiotics.\n\nAccording to Danish Nationwide Guidelines (initiated in 2024), initial oral antibiotics are recommended to patients with no risk factors for complicated disease. Risk factors include for complicated disease include:\n\n1. Severe illness or sepsis\n2. Rapid symptom progression\n3. Pronounced symptoms, including severe pain\n4. Pronounced soft tissue involvement\n5. Foreign material or post-surgical infection\n6. Infection with a resistent or rare pathogen, e.g., Salmonella or MRSA\n7. Severe comorbidity, including immunodeficiency\n\nPatients who have received intravenous antibiotic therapy for less than 24 h before oral antibiotics will be included","3 Months","17 Years",{"count":54,"type":21},100,"5 Years","OBSERVATIONAL","Initial oral antibiotic treatment for children and adolescents with uncomplicated bone and joint infections (BJI) has been found non-inferior to initial IV antibiotics in one randomized controlled trial (RCT). The real-world effectiveness of initial oral antibiotics for children and adolescents with BJI is unclear.\n\nThis nationwide, prospective, multicenter, real-world cohort study aims to compare the effectiveness and safety of initial oral antibiotic treatment for children and adolescents with uncomplicated BJI in a real-world setting with those who received initial oral antibiotics in our RCT.",[59,28,27,60,29],"Osteomyelitis Acute","Joint Infection",[62,63,64,30],"Bone and joint infections","Children","Oral antibiotics","2025-04-05",{"date":67,"type":35},"2025-04-09",{"date":69,"type":35},"2024-11-15",{"date":71,"type":21},"2027-05",{"name":73,"class":42},"Rigshospitalet, Denmark",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":85,"conditions":86,"keywords":94,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":74},"100574372","hierarchy-of-effects-of-laboratory-markers-and-their-interaction-with-comorbidity-concerning-outcome-and-personalized-treatment-of-trauma-patients-in-emergency-care-and-rehabilitation-100574372","NCT06758427","Hierarchy of Effects of Laboratory Markers and Their Interaction With Comorbidity Concerning Outcome and Personalized Treatment of Trauma Patients in Emergency Care and Rehabilitation","HELICOPTER","Inclusion Criteria:\n\n* acute long bone fracture (humerus, ulna, radius, femur, tibia) with surgical treatment\n\nExclusion Criteria:\n\n* associated severe injury (ISS \\> 16)\n* associated traumatic brain injury\n* associated traumatic spine injury\n* dementia","67 Years",{"count":84,"type":21},2300,"At least ten percent of trauma patients suffer from any sort of complication. The study aims to identify a risk factor profile to early identify trauma patients at risk.",[87,88,89,90,91,27,92,93],"Postoperative Complications","Surgical Site Infection","Wound Infection","Non-healing Wound","Pseudarthrosis","Pneumonia","Nosocomial Infection",[95],"long bone fracture, trauma","NOT_YET_RECRUITING","2024-12-27",{"date":99,"type":35},"2025-01-03",{"date":101,"type":21},"2025-02-01",{"date":103,"type":21},"2027-10-31",{"name":105,"class":42},"Department of Trauma and Reconstructive Surgery at Eberhard Karls University Tuebingen, BG Klinik Tu",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":74},"100507177","avis-phageinlyon-clinic-100507177","NCT05883995","Avis-PHAGEinLYON Clinic","Inclusion Criteria:\n\n* \\- Patient referred to the Hospices Civils de Lyon for a phage therapy request from 01\u002F01\u002F2015 to 01\u002F01\u002F2028.\n* Avis-PHAGEinLYON clinic study information notice provided to the patient\n\nExclusion Criteria:\n\n* \\- Opposition of trial participant",{"count":113,"type":21},1500,"Avis-PHAGEinLYON Clinic study is a single site non-interventional retrospective and prospective study, initiated by the Hospices Civils de Lyon. Population targeted are patients referred to the Hospices Civils de Lyon for a medical advice for a phage therapy from 2015 to 2028. The primary objective is to quantify the phage therapy requests received at the Hospices Civils de Lyon. 1500 patients will be included in the study.",[27],[117,118],"bacteriophage","medical advice","2023-05-22",{"date":121,"type":35},"2023-06-01",{"date":123,"type":35},"2023-02-01",{"date":125,"type":21},"2029-02-01",{"name":127,"class":42},"Hospices Civils de Lyon"]